Congratulations to the Three Lions on their fantastic run and bronze medal finish! Well done lads. #England

Zflix Football@zflixfootball.bsky.social · 3mo ago

𝐂𝐑𝐀𝐙𝐈𝐄𝐒𝐓 𝐖𝐎𝐑𝐋𝐃 𝐂𝐔𝐏 𝐆𝐀𝐌𝐄 𝐈𝐍 𝐇𝐈𝐒𝐓𝐎𝐑𝐘. 🤯 Game. Set. Match. England! 🎾 This is exactly why we love football so much. What a magnificent match! 😍🍿 Saka scored a hat-trick, and England won the bronze medal. 👏🥉 Declan Rice scored his first World Cup goal, while Ezri Konsa netted his first goal for Engla

Nosha Farhadfar updates us on ongoing Ph1 multicenter study of SENTI-202, a first-in-class, CD33 and/or FLT3 & not endomucin, selective off-the-shelf logic gated CAR NK cell therapy in 20 adults w/ R/R AML/MDS w/ FLT3 and/or CD33, max 3 prior tx (max 2 for MDS IB). No DLTs seen. (1/2) #ASH25.

Peihua Lu back to the podium to discuss CTD402 (being developed in US by Imviva), a CD7-targeted CAR T-cell product for R/R T-ALL in pediatric/adult pts. Focused on 41 pts in RP2D cohort (400 million cells). 9/41 w/ ETP-ALL, 10/41 w/ prior HCT. 5 pts w/ G3+ CRS; 0 (!) w/ ICANS or HLH. #ASH25 (1/2)

Robert Chiesa of Great Ormond Street presents on allogeneic CD7-targeted "base edited" CAR T-cells for R/R T-ALL (gene editing to disrupt TCRab/CD52/CD7). 11 children enrolled (9 treated) +2 adults; one infusion of CD7 CAR T-cells. 3 w/prior HCT. All w/active BM dz at lymphodepletion. (1/2) #ASh25

Dr. Tingting Yang presents on sequential CD7-targeted CAR T-cell therapy followed by HCT without conditioning and GvHD ppx for 19 pts w/ R/R AML or T-ALL/LBL. aGVHD in 59% as below; 17/19 full donor chimerism at 1 month; 11/19 remain alive (10 in CR). Median PFS/OS 12.3/14.6 months. (1/2) #ASH25

Dr. Peihua Lu presents on CD7 CAR T-cell therapy in 30 pediatric and adult pts w/ R/R T-ALL using NS7CAR (natural selected CD7 CAR product w/o gene editing), all with CNS-2/3 involvement. All received bridging. No manufacturing failure. Vein to vein time 2 weeks. (1/2) median#ASH25

Dr. Quynh Long Khuong from UPenn presents on possible use of BB/ACEi to reduce cardiotoxicity in pediatric pts w/ AML receiving anthracycline-based induction using multicenter cohort. 908 pts studied; modest but significant reduction in LVEF reduction and mortality w/ BB. (1/2) #ASH25

Zachary Graff of @medicalcollegeofwi.bsky.social presents on CNS disease status in pediatric pts w/ AML treated on AAML1831. CNS-1/2/3 (using ALL definition) status predicted EFS when retrospectively applied to prior COG studies. AAML1831 delayed LP to d8 and used more triple IT tx. (1/2) #ASH25

Dr. Talha Badar from @mayocliniccancer.bsky.social presents on selection of HMA for new-dx TP53m AML. 321 pts (138 aza/183 dec), median age 71, no sig diff in genetic profile. Slightly higher CR/CRi (54 vs 39% w/ dec vs aza). EFS/OS similarly poor. Complex CG assoc w/ worse EFS/OS. (1/2) #ASH25

Dr. Quan Do of VCU Healt Systems presents on risk of heart failure (HF) post-idarubicin vs daunorubicin; structurally, ida expected to be less cardiotoxic, though clinical trials haven't suggested the same. TriNetX database used to assess HF rate w/in 10y of AML tx w/ dauno/ida in 7+3. (1/2) #ASH25

Dr. Montesinos presents on "indolent" AML based on PETHEMA registry data. A subset of pts age ≥60y have longer-term survival (≥9 mon) w/ best supportive care (BSC) alone (192/2506). ↓ WBC/PB+BM blasts/LDH, ↑albumin in indolent AML; PLTs/albumin/BM blasts remained sig in multivar analysis. #ASH25

Dr. Douglas Tremblay from Mount Sinai presents on association of nadir bone marrow aspirate (BMA) characteristics w/ reinduction outcomes based on 233 pts from ECOG-ACRIN AML studies (E1900, E2906). Mostly intermediate/adverse risk. Median 15% reduction w/ reinduction, 52% CR w/ reind. (1/2) #ASH25

Aman Wadhwa presents on risk factors for CNS relapse in 21,830 pts w/ de novo B-ALL across COG studies 2004-2019. Certain risk factors for BM relapse (age, female sex) did NOT predict CNS relapse. Cumulative incidence of CNS relapse 2.2%, median time 24.6 months. (1/2) #ASH25

Thai Hoa Tran from CHU Sainte-Justine in Montreal reports on 196 pediatric/AYA pts (age <25y) w/ T-ALL harboring ABL-class fusions (~5% of T-ALL) from multinational retrospective study within Pointe di Legno consortium. 69% w/ NUP214::ABL1, 8% BCR::ABL1. 72% male. Median dx WBC 83. (1/2) #ASH25

Nicolò Peccatori presents on PAX5r B-ALL in 162 pediatric pts treated on consecutive AIEOP-BFM ALL trials in Italy/Germany/Austria. 60 PAX5 fusion partners seen. Trend toward more IKZF1-plus, ↑WBC and NCI-HR. Analysis of prospectively identified pts (vs controls): no diff in MRD resp (1/2) #ASH25

Sankalp Anora of @mdanderson.bsky.social presents on risk factors for relapse in 213 pts receiving frontline blinatumomab in any phase of treatment. 2y cumulative incidence relapse ~11.4%. Descriptive analysis of factors associated w/ relapse below. (1/2) #ASH25

Sumit Gupta from @sickkidsto.bsky.social presents an update from AALL1731 (previously showed DFS benefit w/ blina + chemo in SR-avg and SR-high in pediatric B-ALL). In pts randomized to blina, Hispanic ancestry, EOI MRD were no longer negative prognostic factors. Re: genetic risks... (1/2) #ASH25

Ruth Wang'ondu from @stjuderesearch.bsky.social presents on pediatric pts w/ NCI-SR ALL at dx (age 1-<10, WBC <50k/mcL) receiving 3-drug induction on AALL0932 -> reclassified as NCI-HR/VHR based on pathologic/MRD findings (could be enrolled on AALL1131 -> aBFM backbone w/ randomizations. 1/2 #ASH25

Amanda DiNofia @childrensphila.bsky.social presents on tisa-cel for 1st CNS relapse in pediatric B-ALL (group that did NOT benefit from blina in AALL1331). 43 pts w/ CNS relapse (age 0-29, 1st in 39/43) w/o cXRT for relapse rec'd tisa-cel. At d28, 41/42 evaluable pts in CNS remission. (1/2) #ASH25

Dr. Ying Wang presents updated Ph1b/2 study data w/ MK-1045 (humanized bispecific IgG4 CD19xCD3 T-cell engager) in R/R B-ALL. Long-half life allows weekly IV admin (not IVCI). 75 pts treated, 10 dose levels; 73 efficacy-evaluable. CR/CRi/CRh in 55% (83% w/ dose ≥60mg). 9 w/ (1/2) #ASH25 prior blina

Dr. Lucy Cain of @childrensphila.bsky.social presents on humanized CD19-targeted CAR T-cell product (huCART19) for R/R B-ALL (HR and post-CAR relapse): 100 pts age 0-29 treated (52 CAR naive, 48 CAR exposed). Majority pts had MRD or less at tx. 94%/77% CR/Cri d28 (CAR naive/exposed). (1/2) #ASH25

Marlise Luskin from @danafarber.bsky.social presents on inotuzumab/venetoclax (ino/ven) in R/R B-ALL/LBL -> induction w/ 1-2 28d cycles of ven added to ino. If CR, consolidation w/ 21d ven + ino for up to 6 cycles. Dex given prephase + w/ induction. 23 pts enrolled (4 Ph+), no DLTs. (1/2) #ASH25

Gowrishankar Palaniswamy presents on EfficientNetB1, an AI application reviewing blood smears/marrow (BM) studies in pts w/ ALL. Goal to distinguish benign lymphocytes from ALL and assign early pre-B, pre-B, and pro-B classification. Highly reproducible without loss over epochs. (1/2) #ASH25

Nicholas Short of @mdanderson.bsky.social presents paired analysis of NGS for IgH/TCR and PCR for BCR::ABL1 in 80 adults w/ Ph+ ALL w/ clonoSEQ MRD neg. Strong correlation between FISH+ in segmented nuclei at dx and PCR+/NGS- state later. NGS-/PCR- vs NGS-/PCR+ w/ similar OS/relapse. (1/2) #ASH25

Rohaum Hamidi of @stanfordmedicine.bsky.social presents study of clonoSEQ to measure disease burden and B-cell load prior to LD chemo and CAR T-cell therapy. 60 pts age 1-26 treated w/ CD19, CD22, or dual CD19/22 CAR T-cells at Stanford. Peak sequence abundance assoc w/ better EFS/OS. (1/2) #ASH25

Dr. Roberta Azevedo of @mdanderson.bsky.social presents on predictors of relapse post-blina/inotuzumab (ino) w/ or w/o alloHCT: 203 adults in first salvage. 65 pts received blina/ino, 71 received ino alone, 36 received BLIN alone, 117 received chemo w/ ino or BLIN ->172/203 CR. (1/2) #ASH25

💅

#ASH25 #bmtsm Jiang: no role for FLT3i maintenance in pts MRD neg at d30 who don’t have high risk factors (ELN22 adv, relapse, MRD pos pre-HCt), but in high risk pts there was benefit for maintenance even if d30 MRD neg. FLT3i used for at least one year.

Matthew Wieduwilt presents follow-up data from Alliance (A041703) study for adults ≥60y w/ Ph-neg B-ALL. Single agent ino x1-2 cycles adapted to response ->3-4 cycles of blina. Summary of other frontline inotuzumab (ino)-based regimens below. 33 patients (median age 71, range 60-84). (1/2) #ASh25

Ibrahim Aldoss of @cityofhope.bsky.social presents study of 18 pts age 55 and up w B-ALL in CR1 following any initial therapy (w/o immediate plan for HCT) treated w/ single dose of 4-1BB CD19-targeted CAR T-cells as consolidation. No DLT in safety lead-in (n=6); 12 add'l pts enrolled. (1/2) #ASH25